CompletedPhase 3

A Study of HS-20094 in Chinese Adults With Overweight or Obesity

A Randomized, Double-blind, Placebo-controlled Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of HS-20094 in Overweight and Obese Subjects

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Asset

Olatorepatide

Listed sites

Recruiting sites

Actual enrollment

604

Study population

Obesity / overweight

Eligibility highlights

•BMI ≥28

Primary endpoint

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06839664

Org study IDHS-20094-301

Timeline

Milestones

Study start2024-11-16actual

Study first posted2025-02-21actual

Primary completion2026-01-04actual

Study completion2026-01-30actual

Last update posted2026-06-08actual

Assets

Investigational agents

Olatorepatide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Male or female 18 to 65 years of age at the time of consent(cutoff value included).

•Body mass Index(BMI)≥28 kilograms per square meter(kg/m2),or ≥24 kg/m2 and previous diagnosis with at least one of the following comorbidities: prediabetes, hypertension, dyslipidemia, non-alcoholic fatty liver disease, obstructive sleep apnea.

•Weight change ≤5.0% after diet and exercise control for at least 12 weeks before screening.

Exclusion criteria

•Diabetes mellitus

•Weight change >5.0% after diet and exercise control for at least 12 weeks before screening

•Have used or are currently using weight loss drugs within 3 months before screening

•History of pancreatitis

•Family or personal history of medullary thyroid carcinoma(MTC)or multiple endocrine neoplasia syndrome type 2(MEN-2)

•History of moderate to severe depression, or have a history of serious mental illness

•Any lifetime history of a suicide attempt

•Have a history of significant atopy (severe allergic manifestations), multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions

•Have a history of any malignancy within the past 5 years

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.